Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesClinical implications of hypoxia inducible factor in renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations, 07/01/09
Smaldone MC et al. - In a review of the clinical implications of hypoxia inducible factor (HIF) in renal cell carcinoma (RCC), this report provides a directed review of recent discoveries defining the role of HIF in renal tumorigenesis and their relevance to clinical advances in targeted therapy for advanced RCC.
Methods- Management of RCC has made considerable strides in the past decade, due in large part to identification of the von Hippel Lindau (VHL) tumor suppressor as a negative regulator of HIF-α protein expression.
- Stabilization of HIF-α appears to be critical for renal tumorigenesis, and is observed even in VHL-independent RCC.
- An understanding of the pathways that regulate expression and activation of the different HIF-α isoforms is key to delineating the mechanism of renal transformation and for development of novel therapeutics.
- A number of agents targeting HIF-α or its transcriptionally-regulated genes have shown promise in treatment of RCC.
- More effective treatment strategies are still needed.
Related Articles
The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1 alpha in human rheumatoid arthritis fibroblast-like synoviocyte
Rheumatology International, 10/30/09
Relevance Score: 83%
Neuroprotective effect of combined hypoxia-induced VEGF and bone marrow-derived mesenchymal stem cell treatment
Child's Nervous System, 11/20/09
Relevance Score: 80%
Involvement of hypoxia-inducible factor-1 HiF(1[alpha]) in IgE-mediated primary human basophil responses
European Journal of Immunology, 11/18/09
Relevance Score: 80%
Hypoxia inducible factor-1alpha induction by tumour necrosis factor-alpha, but not by toll-like receptor agonists, modulates cellular respiration in cultured human hepatocytes
Liver International, 10/08/09
Relevance Score: 80%
c-Jun Protects Hypoxia-Inducible Factor-1 from Degradation via Its Oxygen-Dependent Degradation Domain in a Nontranscriptional Manner
Cancer Research, 10/05/09
Relevance Score: 79%
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor